-
Product Insights
NewMuscle Atrophy – Drugs In Development, 2024
Empower your strategies with our Muscle Atrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness, and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy, and arthritis. Treatment includes exercise, dietary changes, and surgery. The Muscle Atrophy drugs in development market research report provide...
-
Product Insights
NewRecessive X Chromosome Disorders – Drugs In Development, 2024
Empower your strategies with our Recessive X Chromosome Disorders – Drugs In Development, 2024 report and make more profitable business decisions. A recessive X chromosome disorder, also known as an X-linked recessive disorder, is a genetic condition caused by a mutation on one of the X chromosomes, one of the two sex chromosomes. Typically, males have one X and one Y chromosome (XY), while females have two X chromosomes (XX). In recessive X-linked disorders, the mutated gene is located on the...
-
Product Insights
NewDuchenne Muscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Duchenne Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. Risk factors include gender and family history. Treatments include steroid medication, respiratory therapy, and surgery. The Duchenne Muscular Dystrophy drugs in development market research report provide comprehensive information...
-
Product Insights
NewNet Present Value Model: Avidity Biosciences Inc’s AOC-1020
Empower your strategies with our Net Present Value Model: Avidity Biosciences Inc's AOC-1020 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2059 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2059 in Pancreatic Ductal Adenocarcinoma Drug Details: IPN-01087 is under development for recurrent head and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AOC-1020 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1020 in Facioscapulohumeral Muscular Dystrophy (FSHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1020 in Facioscapulohumeral Muscular Dystrophy (FSHD) Drug Details: AOC-1020 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Binge Eating Disorder
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Binge Eating Disorder Drug Details: Psilocybin (TRP-8802) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NG-641 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NG-641 in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NG-641 in Hepatocellular Carcinoma Drug Details:NG-641 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1810631 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1810631 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BI-1810631 in Solid Tumor Drug Details:BI-1810631 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AOC-1001 in Myotonic Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1001 in Myotonic Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1001 in Myotonic Dystrophy Drug Details: AOC-1001 is under development for the...